We are live on ! Find out more
CMPX icon

Compass Therapeutics
CMPX

82 hedge funds and large institutions have $93.4M invested in Compass Therapeutics in 2024 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 33 increasing their positions, 18 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

83% more repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 18

40% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 10

5% more funds holding

Funds holding: 78 → 82 (+4)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

1.23% less ownership

Funds ownership: 68.72% → 67.49% (-1.2%)

50% less capital invested

Capital invested by funds: $187M → $93.4M (-$93.8M)

Holders
82
Holders Change
+4
Holders Change %
+5.13%
% of All Funds
1.18%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
14
Increased
33
Reduced
18
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
MB
MPM BioImpact
Massachusetts
+$4.43M
2
Blackstone Inc
Blackstone Inc
New York
+$2.19M
3
BlackRock
BlackRock
New York
+$849K
4
Millennium Management
Millennium Management
New York
+$351K
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$315K

Top Sellers

1
OM
Opaleye Management
Massachusetts
-$6.28M
2
CAM
Cormorant Asset Management
Massachusetts
-$5.15M
3
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$1.86M
4
Fidelity Investments
Fidelity Investments
Massachusetts
-$562K
5
Wellington Management Group
Wellington Management Group
Massachusetts
-$112K
Name Holding Trade Value Shares
Change 		Change in
Stake
Connor, Clark & Lunn Investment Management (CC&L)
26
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$232K -$13.5K -9,275 -4%
Two Sigma Investments
27
Two Sigma Investments
New York
$215K +$107K +73,408 +52%
PI
28
Pennant Investors
New Jersey
$199K – – –
Morgan Stanley
29
Morgan Stanley
New York
$168K +$5.38K +3,685 +2%
Jane Street
30
Jane Street
New York
$153K +$193K +132,391 +640%
Renaissance Technologies
31
Renaissance Technologies
New York
$141K +$103K +70,200 +100%
RhumbLine Advisers
32
RhumbLine Advisers
Massachusetts
$132K +$18K +12,315 +10%
GSC
33
Ground Swell Capital
South Carolina
$124K +$182K +124,394 New
HF
34
HRT Financial
New York
$122K +$178K +122,038 New
DCM
35
DAFNA Capital Management
California
$117K – – –
Two Sigma Advisers
36
Two Sigma Advisers
New York
$114K +$79.6K +54,500 +92%
ETC
37
Exchange Traded Concepts
Oklahoma
$112K -$50.9K -34,854 -24%
Deutsche Bank
38
Deutsche Bank
Germany
$86.2K +$63.5K +43,476 +102%
PFCS
39
Pale Fire Capital SE
Czech Republic
$82.8K -$63.1K -43,191 -34%
PAM
40
Panagora Asset Management
Massachusetts
$68.3K +$99.7K +68,268 New
GCP
41
GSA Capital Partners
United Kingdom
$66K +$96.3K +65,922 New
Bank of America
42
Bank of America
North Carolina
$64.7K +$28.2K +19,310 +43%
Squarepoint
43
Squarepoint
New York
$64.1K +$19.5K +13,321 +26%
Barclays
44
Barclays
United Kingdom
$57.6K -$26.7K -18,282 -24%
CF
45
Corebridge Financial
Texas
$54.9K +$80.1K +54,868 New
VF
46
Virtu Financial
New York
$51K +$74.8K +51,233 New
Susquehanna International Group
47
Susquehanna International Group
Pennsylvania
$50.5K +$73.7K +50,455 New
UBS Group
48
UBS Group
Switzerland
$50.2K -$87.6K -59,983 -54%
LPL Financial
49
LPL Financial
California
$50K +$73K +50,000 New
TRCT
50
Tower Research Capital (TRC)
New York
$46K +$66K +45,220 +5,674%
1
2
3 4

CMPX Hedge Fund Activity: Q2 2024 in Review

82 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Compass Therapeutics (CMPX) for Q2 2024, worth a combined $93.4M — down 50% from $187M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new CMPX positions and 10 closed out — a net gain of 4 holders — while 33 added to existing stakes and 18 trimmed.

The largest buyer was MPM BioImpact, adding an estimated $4.43M. The largest seller was Opaleye Management, exiting entirely with an estimated $6.28M sold.

  • 82 institutional investors held Compass Therapeutics (CMPX) as of Q2 2024, up from 78 in Q1 2024.
  • Funds reported $93.4M of Compass Therapeutics stock for Q2 2024, down 50% quarter-over-quarter.
  • 14 funds opened new Compass Therapeutics positions in Q2 2024 and 10 closed out, a net change of +4 holders.
  • The largest Compass Therapeutics buyer in Q2 2024 was MPM BioImpact, an estimated $4.43M added.
  • The largest Compass Therapeutics seller in Q2 2024 was Opaleye Management, an estimated $6.28M sold.

Based on aggregated 13F filings for Q2 2024.